Andere talen Phio Pharmaceuticals Corp.

Aandelen

PHIO

US71880W4024

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,6399 ^USD	+0,33%		-5,05%	-15,80%

16/04	Phio Pharmaceuticals kondigt komende presentaties aan op de 81e jaarlijkse bijeenkomst van de Society for Investigative Dermatology (SID)	CI
01/04	Phio Pharmaceuticals Corp. Rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)	16/04
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	16/04
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)	11/04
National Spotlight Features Phio’s Innovative RNAi Technology Platform	03/04
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update	02/04
North American Morning Briefing : Stocks Seen -2-	02/04
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	21/03
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	21/03
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research	13/03
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research	13/03
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders	06/03
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders	06/03
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders	06/03
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	31/01
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds	07/12
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	09/11
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas	09/11
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Phio Pharmaceuticals Corp.

Aandelen

PHIO

US71880W4024

Andere talen

Filters